Jefferies raised the price target for the Inozyme Pharma Inc. (NASDAQ:INZY) stock from “a Hold” to “a Buy”. The rating was released on March 23, 2023, according to finviz.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Inozyme Pharma Inc. (NASDAQ:INZY) raised 6.34% to close Thursday’s market session at $6.37, higher as compared to yesterday’s close. The stock price fluctuated between $5.98 and $6.545 throughout the trading session with the volume trading being 612978 shares, which represented a significant variation when compared to the three months average volume of 782.05K shares. The firm’s stock price fluctuated 1.92% within the last five trades and 12.35% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 330.41% in the last 6 months and 122.73% was added to its value over the previous 3 months. INZY stock is trading at a margin of 1.79%, 13.98% and 104.50% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
As of the close of trading, INZY deals in the Healthcare domain. The stock is trading -12.02 percent below its 52-week high and 542.79 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 10.4. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Inozyme Pharma Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $284.29 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 2.70, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.90 percent of Inozyme Pharma Inc. shares are owned by insiders, and 86.70 percent are held by financial institutions. Hopfner Robert Lorne, the Director at Inozyme Pharma Inc. (INZY) has bought 228,702 shares of firm on May 12 at a price of $6.25 against the total amount of $1.43 million. In another inside trade, Hopfner Robert Lorne, Director of Inozyme Pharma Inc. (NASDAQ:INZY) bought 219,230 shares of the firm on May 11 for a total worth of $1.42 million at a price of $6.48. An inside trade which took place on Mar 29, Director of Inozyme Pharma Inc. Hopfner Robert Lorne bought 344,592 shares of firm against total price of $1.56 million at the cost of $4.54 per share.